Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21362773 | 0.81 | PTGS1 (0.39) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL375420 | 0.72 | RXFP1 (0.45) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL7489316 | 0.70 | RXFP1 (0.42) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL1051401 | 0.68 | PTGER1 (0.39) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL18776163 | 0.68 | PTGS1 (0.38) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| Hydrochloric Acid SCHEMBL31555571 | 0.68 | RXFP1 (0.41) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL31352098 | 0.67 | PTGS1 (0.37) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL18786076 | 0.67 | HCAR2 (0.39) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL18776166 | 0.67 | PTGS1 (0.37) | RXFP1BRD4PTGS1PTGS2ALOX15 | |
| SCHEMBL29716077 | 0.67 | KDM4E (0.38) | BRD4TSHRKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | TAKEDA PHARMACEUTICALS CO (JP) | 2024-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240228488-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | KLKB1, KLK5, KLK1 | RXFP1 1944/4885BRD4 2173/4885PTGS1 1221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.